Alivecor

PulseAI's Groundbreaking AI Algorithm Enhances Consumer ECG Diagnostics

Retrieved on: 
Thursday, January 11, 2024
Classification, ECG, Patient, Research, Burden, Cardiology, Alivecor, Health, Intelligence, Atrial fibrillation, Stroke, AI, Algorithm, Samsung, University Hospital of Basel, Apple, Physician, Medical device

BELFAST, Northern Ireland, Jan. 11, 2024 /PRNewswire/ -- PulseAI, a leader in artificial intelligence healthcare solutions, today announced a significant advancement in consumer device electrocardiogram (ECG) monitoring. Published in the Cardiovascular Digital Health Journal, the new study titled "Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm" showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.

Key Points: 
  • Published in the Cardiovascular Digital Health Journal, the new study titled " Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm " showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.
  • The results demonstrate that PulseAI's neural network algorithm significantly reduces inconclusive diagnoses from commercially available consumer ECG devices by Apple, Samsung, AliveCor and Fitbit.
  • The research highlights the challenge of high rates of inconclusive readings from consumer ECG devices.
  • PulseAI's algorithm offers a reliable, cross-platform solution that integrates seamlessly with various consumer and clinical ECG devices.

PulseAI's Groundbreaking AI Algorithm Enhances Consumer ECG Diagnostics

Retrieved on: 
Thursday, January 11, 2024
Classification, ECG, Patient, Research, Burden, Cardiology, Alivecor, Health, Intelligence, Atrial fibrillation, Stroke, AI, Algorithm, Samsung, University Hospital of Basel, Apple, Physician, Medical device

BELFAST, Northern Ireland , Jan. 11, 2024 /PRNewswire/ -- PulseAI, a leader in artificial intelligence healthcare solutions, today announced a significant advancement in consumer device electrocardiogram (ECG) monitoring. Published in the Cardiovascular Digital Health Journal, the new study titled "Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm" showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.

Key Points: 
  • Published in the Cardiovascular Digital Health Journal, the new study titled " Reducing the Burden of Inconclusive Smart-Device Single-lead ECG Tracings via a Novel Artificial Intelligence Algorithm " showcases the impactful role of PulseAI's neural network algorithm in cardiac monitoring.
  • The results demonstrate that PulseAI's neural network algorithm significantly reduces inconclusive diagnoses from commercially available consumer ECG devices by Apple, Samsung, AliveCor and Fitbit.
  • The research highlights the challenge of high rates of inconclusive readings from consumer ECG devices.
  • PulseAI's algorithm offers a reliable, cross-platform solution that integrates seamlessly with various consumer and clinical ECG devices.

Octave® Bioscience, Inc. Announces Chairman of the Board, CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for its Precision Care Solution

Retrieved on: 
Tuesday, December 5, 2023
Research, Mental Health, Technology, Neurology, Other Technology, Biotechnology, General Health, Pharmaceutical, Health, Science, Blue Shield, Mentorship, Multiple sclerosis, Michael J. Critelli, Growth, McKesson Corporation, Quality of life, Management, Alivecor, Octave

Simultaneously, the company announced that industry leader, Doug Biehn, has been named President and CEO, effective immediately.

Key Points: 
  • Simultaneously, the company announced that industry leader, Doug Biehn, has been named President and CEO, effective immediately.
  • “Today, we are a true commercial company, which calls for new strategies, skills, and leadership.
  • Additionally, he is a Board Advisor for a number of early-stage digital health companies and mentors graduate students in the Stanford Business School Lean Launchpad program.
  • Fox Foundation to develop a custom protein biomarker panel that will measure Parkinson’s disease activity and progression in the clinic.

IDTechEx Explores Hyper Personalized Approaches to Healthcare

Retrieved on: 
Tuesday, November 28, 2023
ECG, Woman, DSM-IV codes, Research, DNA, Comfort, Gene, Pregnancy, Patient, Science, Heart rate, Genetic testing, Movement, Health, COVID-19, Smartwatch, Parent, Cancer, Diabetes, Cell, Wireless ambulatory ECG, Blood pressure, Nursing, Medical imaging, Medical device, Vaccine, Alivecor

Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.

Key Points: 
  • Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.
  • Oncology is a sector that, for the past twenty years, has utilized this process to make incredible advancements in prescribing personalized medications.
  • With the combination of self-monitoring and DNA sequencing, the future of healthcare industries is becoming more personalized.
  • For the full portfolio of healthcare market research from IDTechEx, please visit www.IDTechEx.com/Research/Healthcare .

IDTechEx Explores Hyper Personalized Approaches to Healthcare

Retrieved on: 
Tuesday, November 28, 2023
ECG, Woman, DSM-IV codes, Research, DNA, Comfort, Gene, Pregnancy, Patient, Science, Heart rate, Genetic testing, Movement, Health, COVID-19, Smartwatch, Parent, Cancer, Diabetes, Cell, Wireless ambulatory ECG, Blood pressure, Nursing, Medical imaging, Medical device, Vaccine, Alivecor

Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.

Key Points: 
  • Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.
  • Oncology is a sector that, for the past twenty years, has utilized this process to make incredible advancements in prescribing personalized medications.
  • With the combination of self-monitoring and DNA sequencing, the future of healthcare industries is becoming more personalized.
  • For the full portfolio of healthcare market research from IDTechEx, please visit www.IDTechEx.com/Research/Healthcare .

AliveCor Appoints Michael Rolla as Chief Revenue Officer, Enterprise

Retrieved on: 
Friday, November 10, 2023
CCS, ECG, BD (company), Growth, Bard (company), Alivecor, Teladoc Health, FDA, Management

MOUNTAIN VIEW, Calif., Nov. 10, 2023 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Michael Rolla, who will serve as AliveCor's Chief Revenue Officer, Enterprise.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 10, 2023 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Michael Rolla, who will serve as AliveCor's Chief Revenue Officer, Enterprise.
  • Rolla will provide strategic leadership for AliveCor's employer, payor, biopharma and healthcare provider enterprise businesses.
  • Rolla is a seasoned leader who has adeptly navigated the intricate landscape of healthcare technology, consistently delivering transformative results.
  • Having previously served as the Chief Growth Officer for CCS and later as the Chief Revenue Officer of UpHealth Inc., Rolla played a pivotal role in shaping growth and influence in public and private sectors.

Cardiosense Begins Enrollment in Nationwide Heart Failure Study

Retrieved on: 
Tuesday, September 26, 2023
Heart failure, GE HealthCare, Executive, Senior, Life, Hospital, Chief technology officer, GE, Bayer, Trial of the century, Verily, Patient, Algorithm, American College of Cardiology, Apple, Cardiology, FDA, Medical device, Nursing, Operation, Northwestern Medicine, Engineering, Alivecor

CHICAGO, Sept. 26, 2023 /PRNewswire/ -- Cardiosense, a digital health company developing a non-invasive monitoring platform for the early detection of heart disease, recently started enrolling patients in SEISMIC-HF I, its nationwide clinical study to refine and validate algorithms to assess intracardiac filling pressure, an early physiological marker for acute heart failure decompensation. The algorithms leverage data captured by CardioTag, Cardiosense's non-invasive patch that measures key parameters of cardiac function. Cardiosense was awarded FDA Breakthrough Device Designation in 2022.

Key Points: 
  • CHICAGO, Sept. 26, 2023 /PRNewswire/ -- Cardiosense, a digital health company developing a non-invasive monitoring platform for the early detection of heart disease, recently started enrolling patients in SEISMIC-HF I, its nationwide clinical study to refine and validate algorithms to assess intracardiac filling pressure, an early physiological marker for acute heart failure decompensation.
  • Heart failure affects more than 6 million people in the US and is expected to cost the healthcare system more than $70 billion annually by 2030.
  • "Cardiosense's technology has the potential to be a game-changing solution in remotely monitoring patients with heart failure.
  • I'm excited to participate in the SEISMIC-HF I study and that Northwestern Medicine was the first site to enroll patients."

AliveCor's KardiaMobile® 6L Becomes First Personal ECG Device Recommended for Use in Psychiatric Services in England and Wales

Retrieved on: 
Tuesday, September 26, 2023
Criticism of the National Health Service (England), Travel, Diuretic, National Health Service, Intersex, Anxiety, Electricity, Business, ECG, QT, Tees, Esk and Wear Valleys NHS Foundation Trust, EVA, Psychiatrist, QT interval, Patient, Collection, Physician, National Institute for Health and Care Excellence, NHS, Cardiology, NICE, Hospital, Pharmaceutical industry, Medical imaging, Birth control, Alivecor

1, 2 KardiaMobile 6L is a portable ECG recording device that provides instant detection of cardiac abnormalities and can be used to measure heart changes including cardiac QT interval.1

Key Points: 
  • 1, 2 KardiaMobile 6L is a portable ECG recording device that provides instant detection of cardiac abnormalities and can be used to measure heart changes including cardiac QT interval.1
    "Timely ECG monitoring of patients who are on antipsychotic medication can save lives.
  • Having access to KardiaMobile 6L will mean potentially vulnerable patients can now be seen in the comfort of their homes, reducing their stress whilst ensuring that this essential monitoring is completed anywhere, at any time.
  • KardiaMobile 6L has been recommended as part of NICE's EVA pilot project, created to drive earlier access to promising healthcare innovations for use within the National Health Service in England and Wales.
  • "We have a wealth of clinical data on the use of KardiaMobile 6L in cardiology, with NICE's EVA recommendation we will now support the collection of real-world evidence as to its effectiveness in psychiatric services.

Veterinary Medical Equipment Global Market Report 2023-2032: From Diagnostics to Anesthesia - Explore the Latest Innovative Solutions for Animal Health - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 22, 2023
Other Health, Radiology, Surgery, Medical Devices, Hospitals, Pets, Agriculture, Dental, Natural Resources, Science, Veterinary, Consumer, Other Science, Health, Medical Supplies, Anesthesia, IPhone, Emergency, Animal, Pregnancy, Alivecor, Veterinary medicine

The "Veterinary Medical Equipment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Medical Equipment Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The veterinary medical equipment research report provides veterinary medical equipment statistics, including veterinary medical equipment industry global market size, regional shares, competitors with veterinary medical equipment shares, detailed veterinary medical equipment segments, market trends and opportunities, and any further data you may need to thrive in the veterinary medical equipment industry.
  • The main types of veterinary medical equipment are veterinary diagnostic equipment, veterinary anesthesia equipment, veterinary patient monitoring equipment, and other veterinary medical equipment that is used for animals such as small companion animals, large animals, and other animals.
  • The regions covered in the veterinary medical equipment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Clario and AliveCor collaborate to offer advanced, trial-focused six-lead ECG solutions for monitoring in decentralized clinical trials

Retrieved on: 
Tuesday, August 15, 2023
Partnership, Data collection, ECG, FDA, SVP, Kardia, PII, Clario Tech, Medical device, Mobile phone, Alivecor

PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ -- Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology. This collaboration will enable trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes through KardiaRx, a clinical-trial-focused app. This technology enables pharmaceutical and biotech customers to consider decentralized and hybrid clinical trial strategies in study protocols that would have otherwise been limited to on-site evaluations.

Key Points: 
  • Clario and AliveCor provide a new trial-participant-friendly solution for cutting-edge, at-home data collection with privacy protection, instrumental in situations where traditional 12-lead ECG cannot be collected.
  • PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ -- Clario , a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology.
  • This collaboration will enable trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes through KardiaRx, a clinical-trial-focused app.
  • "Our partnership with AliveCor is a game-changer for at-home ECG data collection," said Ellen Street, EVP Cardiac Safety & Respiratory at Clario.